# Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy

Study · id `cardio:ct-nct01722513` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01722513](<https://clinicaltrials.gov/study/NCT01722513>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01722513

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

## Technical summary

Registry record NCT01722513. Allocation not applicable; single masking; primary purpose prevention. Start 2012-11 (registry gives no type); primary completion 2013-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT01722513, source copy `cardio:ctgov-nct01722513-2012-11-07`, retrieved 2026-10-26)
- Start date: 2012-11 (registry gives no type) (ClinicalTrials.gov record NCT01722513, source copy `cardio:ctgov-nct01722513-2012-11-07`, retrieved 2026-10-26)
- Primary completion: 2013-11 (anticipated) (ClinicalTrials.gov record NCT01722513, source copy `cardio:ctgov-nct01722513-2012-11-07`, retrieved 2026-10-26)
- Completion: 2014-02 (anticipated) (ClinicalTrials.gov record NCT01722513, source copy `cardio:ctgov-nct01722513-2012-11-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01722513, source copy `cardio:ctgov-nct01722513-2012-11-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01722513-2012-11-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy
- Condition: Kidney Diseases
- Condition: Diabetes Mellitus
- Condition: Acute Kidney Injury
- Condition: Kidney Failure, Chronic
- Condition: Renal Insufficiency
- Intervention (Drug): Alprostadil ﹠control
- Lead sponsor: Shanghai 10th People's Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Shanghai 10th People's Hospital (`cardio:org-shanghai-10th-people-s-hospital`)

## Provenance

Content hash: 2d8dc3bbd656b32e580c9bf97bfcfa07c9e3103a3565d5b44f7b7db391e659a6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
